In trading on Monday, shares of Mesabi Trust (Symbol: MSB) crossed above their 200 day moving average of $31.86, changing hands as high as $32.38 per share. Mesabi Trust shares are currently trading up about 4.7% on the day. The chart below shows the one year performance of MS
In trading on Monday, shares of Mesabi Trust (Symbol: MSB) crossed above their 200 day moving average of $31.86, changing hands as high as $32.38 per share. Mesabi Trust shares are currently trading up about 4.7% on the day. The chart below shows the one year performance of MS
Vertiv ( NYSE: VRT ) on Monday said it will invest about $50 million to expand manufacturing operations in Ironton, Ohio, and its headquarters campus in Westerville, Ohio. The company said the projects are expected to create hundreds of jobs through 2029 and increase production capacity for liquid cooling and chilled water systems used in high-density computing. The Ironton facility expansion, exp...
Vertiv ( NYSE: VRT ) on Monday said it will invest about $50 million to expand manufacturing operations in Ironton, Ohio, and its headquarters campus in Westerville, Ohio. The company said the projects are expected to create hundreds of jobs through 2029 and increase production capacity for liquid cooling and chilled water systems used in high-density computing. The Ironton facility expansion, expected to be operational in the second quarter of 2027, is projected to boost capacity for these systems by about 45%, the company said. VRT -0.02% after hours to $233.98. Source: Press Release More on Vertiv Vertiv Holdings Co (VRT) Presents at JPMorgan Industrials Conference 2026 Transcript Vertiv: Remains A Fantastic Pick-And-Shovel AI Play Vertiv: An Upcoming S&P 500 Member, Shares Near Fair Value (Downgrade) Vertiv rallies to record high as HSBC sees strong upside from AI demand Vertiv strengthens data center cooling play with ThermoKey buy
In trading on Monday, shares of the SPDR S&P Semiconductor ETF (Symbol: XSD) crossed below their 200 day moving average of $314.43, changing hands as low as $303.74 per share. SPDR S&P Semiconductor shares are currently trading off about 4.8% on the day. The chart belo
In trading on Monday, shares of the SPDR S&P Semiconductor ETF (Symbol: XSD) crossed below their 200 day moving average of $314.43, changing hands as low as $303.74 per share. SPDR S&P Semiconductor shares are currently trading off about 4.8% on the day. The chart belo
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive.
Phreesia press release ( PHR ): Q4 GAAP EPS of $0.02 misses by $0.04 . Revenue of $127.07M (+15.9% Y/Y) beats by $0.44M . More on Phreesia Seeking Alpha’s Quant Rating on Phreesia Historical earnings data for Phreesia Financial information for Phreesia
Phreesia press release ( PHR ): Q4 GAAP EPS of $0.02 misses by $0.04 . Revenue of $127.07M (+15.9% Y/Y) beats by $0.44M . More on Phreesia Seeking Alpha’s Quant Rating on Phreesia Historical earnings data for Phreesia Financial information for Phreesia
BURLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index, today announced its financial results for the fiscal first quarter 2026, which ended on February 28, 2026. Progress is the trusted provider of AI-powered digital experience and infrastructure software.
BURLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index, today announced its financial results for the fiscal first quarter 2026, which ended on February 28, 2026. Progress is the trusted provider of AI-powered digital experience and infrastructure software.
MONTRÉAL, 30 mars 2026 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE et TSX: TFII), un chef de file nord-américain du secteur du transport et de la logistique, a annoncé aujourd'hui qu'elle communiquera ses résultats financiers pour le premier trimestre clos le 31 mars 2026 par voie d’un communiqué de presse le lundi 27 avril 2026 après la fermeture des marchés. La société tiendra une webdiffus...
MONTRÉAL, 30 mars 2026 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE et TSX: TFII), un chef de file nord-américain du secteur du transport et de la logistique, a annoncé aujourd'hui qu'elle communiquera ses résultats financiers pour le premier trimestre clos le 31 mars 2026 par voie d’un communiqué de presse le lundi 27 avril 2026 après la fermeture des marchés. La société tiendra une webdiffusion pour la communauté des investisseurs avec Alain Bédard, président du conseil, président et chef de la direction, et David Saperstein, chef de la direction financière, le lundi 27 avril 2026 à 17h00, heure de l'Est, pour discuter des résultats.
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the first quarter ended March 31, 2026 via news release on Monday, April 27, 2026 after market close. The company will host a webcast with Alain Bédard, Chairman, President and ...
MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the first quarter ended March 31, 2026 via news release on Monday, April 27, 2026 after market close. The company will host a webcast with Alain Bédard, Chairman, President and Chief Executive Officer, and David Saperstein, Chief Financial Officer, on Monday, April 27, 2026 at 5:00 PM Eastern Time, to discuss results.
SAN JOSE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leading provider of augmented and virtual reality (AR/VR) solutions for education, is announcing its financial results for the three and twelve months ended December 31, 2025.
SAN JOSE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leading provider of augmented and virtual reality (AR/VR) solutions for education, is announcing its financial results for the three and twelve months ended December 31, 2025.
NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter and full year ended December 31, 2025.
NEWTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter and full year ended December 31, 2025.
dem10/E+ via Getty Images I see a similar pattern to what happened nearly a year ago during Trump's tariff sell-off. However, I am not buying the dip yet despite the fundamentals of the high-growth pockets in the market (mainly beneficiaries from the AI data center buildout) remaining intact. Trying to time the bottom of a selloff is often a sucker's bet, but I'm more than happy to take this one. ...
dem10/E+ via Getty Images I see a similar pattern to what happened nearly a year ago during Trump's tariff sell-off. However, I am not buying the dip yet despite the fundamentals of the high-growth pockets in the market (mainly beneficiaries from the AI data center buildout) remaining intact. Trying to time the bottom of a selloff is often a sucker's bet, but I'm more than happy to take this one. Why? So far, I am not seeing any signs of capitulation. Since the war began, the SPY hasn't seen a single 2% drop in one day. Let alone a 4% drop like in April last year. On top of that, the S&P 500 is still in a very awkward place right now from a technical perspective, with poor breadth in pretty much all sectors except energy. Guidance Terminal | Market breadth and returns across all 11 sectors | 1-month timeframe In this piece, I will focus on the most recent data that tries to put a number on the global impact of higher oil prices due to the conflicts in the Middle East. My view is that this data is overly pessimistic. The U.S. consumer is starting to sweat about higher-for-longer gas prices, although I take the survey data with skepticism. Overall, I am staying on the sidelines, as I don't think the lows are behind us. I still see the SPY at $610-$620 in the first half of the year, followed by a rally in the second half, as the oil shock fades (similarly to the tariff fears last year). This is an exogenous event, and I strongly believe it will be transitory, even though "experts" suggest otherwise. I discuss more below. OECD Cuts the Quality of Its Global Outlook The Organisation for Economic Co-operation and Development released its interim report last Thursday, showing a 1.2 percentage point increase in inflation to 4.0% for G20 countries this year. OECD The reason I'm highlighting this report is that it's the first main study since the war that tries to quantify the impact of higher for longer oil prices due to the Strait of Hormuz being blocked. Notably, this orga...
EschCollection/DigitalVision via Getty Images Healthcare diagnostics has been one of my favorite industries to cover, but they have been dealing with macroeconomic headwinds, pricing pressures from payers, and scrutiny over reimbursement. As a result, many of my healthcare diagnostic stocks are struggling to make gains, even as these companies continue to report clinical and commercial progress. T...
EschCollection/DigitalVision via Getty Images Healthcare diagnostics has been one of my favorite industries to cover, but they have been dealing with macroeconomic headwinds, pricing pressures from payers, and scrutiny over reimbursement. As a result, many of my healthcare diagnostic stocks are struggling to make gains, even as these companies continue to report clinical and commercial progress. The market’s neglect has produced some intriguing opportunities to invest in companies that have significant clinical power but also offer scalable business models. Castle Biosciences, Inc. ( CSTL ) is currently showing an opportunity as a leader in precision diagnostics for a variety of cancer diagnostics, including their melanoma product, DecisionDx-Melanoma. The company is set to present updated data at the 2026 American Academy of Dermatology (AAD) Annual Meeting, showing that their DecisionDx-Melanoma test can help stratify mortality risk within AJCC stages for patients with cutaneous melanoma (CM). Although this data presentation might not be a catalyst for the stock, I’m more interested that the company has the evidence to show that DecisionDx-Melanoma enables personalized care for patients and providers, while commercially, we could still see additional adoption, which would help revitalize the share price. As a result, I’m looking to start a pilot position in the immediate term and will look to build a position over the course of 2026 as the company invests in growth. I intend to provide a brief background on Castle Biosciences and their current performance. Then, I will discuss why I’m bullish on DecisionDx-Melanoma and why I’m looking for entry in the immediate term. I will also point out some downside risks that investors need to consider when managing their CSTL position. Finally, I take a look at CSTL’s daily chart to see if I can identify an entry point. Background on Castle Biosciences Castle Biosciences offers patient-centered genomic and molecular tests to ...
Annexon Biosciences press release ( ANNX ): Q4 GAAP EPS of -$0.28 beats by $0.04 . Cash, cash equivalents and short-term investments were $238.3 million as of December 31, 2025, including $86.3 million in gross proceeds from a November 2025 public offering. Based on focused investments in its lead late-stage programs, Annexon expects to fund operations and anticipated milestones into the second ha...
Annexon Biosciences press release ( ANNX ): Q4 GAAP EPS of -$0.28 beats by $0.04 . Cash, cash equivalents and short-term investments were $238.3 million as of December 31, 2025, including $86.3 million in gross proceeds from a November 2025 public offering. Based on focused investments in its lead late-stage programs, Annexon expects to fund operations and anticipated milestones into the second half of 2027. More on Annexon Biosciences Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials - Slideshow Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials Transcript Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases Seeking Alpha’s Quant Rating on Annexon Biosciences Historical earnings data for Annexon Biosciences
Douglas Rissing "The current stance of monetary policy is well positioned to balance the risks to our maximum employment and price stability goals," said John Williams, a permanent member of the Federal Open Market Committee. The president of the Federal Reserve Bank of New York participated in a conversation at an event organized by the Staten Island Economic Development Corporation. "Despite hei...
Douglas Rissing "The current stance of monetary policy is well positioned to balance the risks to our maximum employment and price stability goals," said John Williams, a permanent member of the Federal Open Market Committee. The president of the Federal Reserve Bank of New York participated in a conversation at an event organized by the Staten Island Economic Development Corporation. "Despite heightened uncertainty around the impact of trade and other policies, the economy has been resilient, with growth remaining solid through last year and into the beginning of this year," said Williams. "Consumer spending has been resilient, and business investment has been strong. And the unemployment rate has stabilized over recent months. Inflation remains somewhat elevated due to the effects of tariffs, but those effects should begin to dissipate later this year," he added. Williams said it's an unusual time for the economy, with substantial risks and high uncertainty - particularly around the economic effects of the Middle East conflict. "In assessing the future path of monetary policy, my views, as always, will be based on the evolution of the totality of the data, the economic outlook, and the balance of risks to the achievement of our maximum employment and price stability goals," he said. Turning to one side of the Fed's dual mandate - maximum employment - "We are getting mixed signals, with some key indicators showing signs of steadying while others are suggesting a weakening labor market." The FOMC voting member mentioned a low-hire, low-fire environment in existence currently, and said, "The low hiring rate, along with an increase in long-term unemployment, may be contributing to a somewhat more pessimistic perception among households than other indicators of the labor market might suggest." For the other side of the Fed's mandate - price stability - "Inflation is experiencing its own unusual crosscurrents due to the effects of tariffs and developments in the Middle ...